In 2013, Big Sellers in PGx Market Remain Herceptin, Gleevec with Newer Agents Poised to Take Over | GenomeWeb

In 2013, the top selling pharmacogenetically targeted drugs were well-known personalized medicine products, Herceptin and Gleevec.

Both of these drugs are slated to face generic competition soon, however, and when they do, drugmakers have newer agents in their pipelines to take their place. Meanwhile, across the PGx market, as new drugs are launched addressing smaller and smaller patient subsets, it raises the question whether any other personalized drugs will be able to match Herceptin or Gleevec's revenue success.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.